POLIVY

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, New Zealand, Poland, Romania, UK.

Active ingredients

The drug POLIVY contains one active pharmaceutical ingredient (API):

1	Polatuzumab vedotin UNII KG6VO684Z6 - POLATUZUMAB VEDOTIN
	Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.
	Read more about Polatuzumab vedotin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
POLIVY Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
POLIVY Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX14	Polatuzumab vedotin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02499614
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	186-MBE-0421, 210-MBE-0821
EE	Ravimiamet	1810099, 1834051
FI	Lääkealan turvallisuus- ja kehittämiskeskus	112212, 471385
FR	Base de données publique des médicaments	60380094, 60978348
GB	Medicines & Healthcare Products Regulatory Agency	382216, 393295
HK	Department of Health Drug Office	66664, 67107
IL	מִשְׂרַד הַבְּרִיאוּת	8528
IT	Agenzia del Farmaco	048443016, 048443028
JP	医薬品医療機器総合機構	4291455D1022, 4291455D2029
LT	Valstybinė vaistų kontrolės tarnyba	1089249, 1091495
NZ	Medicines and Medical Devices Safety Authority	20697
PL	Rejestru Produktów Leczniczych	100430720, 100456900
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66558001, W67121001
US	FDA, National Drug Code	50242-103, 50242-105